Status:

COMPLETED

2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation

Lead Sponsor:

Vanderbilt University Medical Center

Collaborating Sponsors:

American Heart Association

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

22+ years

Phase:

PHASE2

Brief Summary

The proposed studies will test this hypothesis by randomizing patients with AF to 2-HOBA or placebo 7 days prior to AF ablation to allow 2-HOBA to reach steady-state levels. We hypothesize that tissue...

Detailed Description

The proposed double-blind, randomized, placebo-controlled trial of 2-HOBA in patients undergoing AF ablation is designed to address the following Specific Aims: Specific Aim 1: To test the hypothesis...

Eligibility Criteria

Inclusion

  • First time AF ablation with radiofrequency or cryo ablation
  • Repeat AF ablation if the patient has persistent AF and ablation of non-pulmonary vein substrate is planned (e.g. posterior wall ablation, mitral or roof line, etc)
  • Able to provide written, informed consent
  • 22 years of age or older

Exclusion

  • Planned surgical or hybrid (surgical + catheter) ablation
  • Amiodarone within past 3 months
  • Use of oral steroids or colchicine
  • Pro-inflammatory, rheumatologic disorder (e.g. RA, SLE, IBD, psoriasis, ankylosing spondylitis)
  • NYHA Class III/IV Heart Failure
  • LVEF \<35%
  • Active ischemia
  • Hypertrophic Cardiomyopathy
  • Cardiac or thoracic surgery within 6 months
  • Expected life span \< 1 year
  • Creatinine clearance \<30 ml/min
  • Prior or planned heart transplantation
  • Pregnant women
  • Aspirin allergy
  • Current use of MAO-I

Key Trial Info

Start Date :

May 15 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2023

Estimated Enrollment :

95 Patients enrolled

Trial Details

Trial ID

NCT04433091

Start Date

May 15 2020

End Date

January 30 2023

Last Update

November 21 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical

Nashville, Tennessee, United States, 37232